miRNA signature associated with outcome of gastric cancer patients following chemotherapy

BackgroundIdentification of patients who likely will or will not benefit from cytotoxic chemotherapy through the use of biomarkers could greatly improve clinical management by better defining appropriate treatment options for patients. microRNAs may be potentially useful biomarkers that help guide individualized therapy for cancer because microRNA expression is dysregulated in cancer. In order to identify miRNA signatures for gastric cancer and for predicting clinical resistance to cisplatin/fluorouracil (CF) chemotherapy, a comprehensive miRNA microarray analysis was performed using endoscopic biopsy samples.MethodsBiopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. At the time of disease progression, post-treatment samples were additionally collected from 8 clinical responders. miRNA expression was determined using a custom-designed Agilent microarray. In order to identify a miRNA signature for chemotherapy resistance, we correlated miRNA expression levels with the time to progression (TTP) of disease after CF therapy.ResultsA miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). Prominent among the upregulated miRNAs associated with chemosensitivity were miRNAs known to regulate apoptosis, including let-7g, miR-342, miR-16, miR-181, miR-1, and miR-34. When this 58-miRNA predictor was applied to a separate set of pre- and post-treatment tumor samples from the 8 clinical responders, all of the 8 pre-treatment samples were correctly predicted as low-risk, whereas samples from the post-treatment tumors that developed chemoresistance were predicted to be in the high-risk category by the 58 miRNA signature, suggesting that selection for the expression of these miRNAs occurred as chemoresistance arose.ConclusionsWe have identified 1) a miRNA expression signature that distinguishes gastric cancer from normal stomach epithelium from healthy volunteers, and 2) a chemoreresistance miRNA expression signature that is correlated with TTP after CF therapy. The chemoresistance miRNA expression signature includes several miRNAs previously shown to regulate apoptosis in vitro, and warrants further validation.

[1]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[2]  M. Washington,et al.  Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer , 2008, Oncogene.

[3]  Masakazu Yamamoto,et al.  Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. , 2006, Cancer genomics & proteomics.

[4]  Yingdong Zhao,et al.  Analysis of Gene Expression Data Using BRB-Array Tools , 2007, Cancer informatics.

[5]  Tasneem Motiwala,et al.  Down-regulation of Micro-RNA-1 (miR-1) in Lung Cancer , 2008, Journal of Biological Chemistry.

[6]  B. Xiao,et al.  Differential expression of microRNA species in human gastric cancer versus non‐tumorous tissues , 2009, Journal of gastroenterology and hepatology.

[7]  M. Radmacher,et al.  Design of studies using DNA microarrays , 2002, Genetic epidemiology.

[8]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[9]  Liu Hong,et al.  miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells , 2008, International journal of cancer.

[10]  H. Hermeking The miR-34 family in cancer and apoptosis , 2010, Cell Death and Differentiation.

[11]  Joel Greshock,et al.  MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. , 2008, Cancer research.

[12]  Jason H. Moore,et al.  Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. , 2007, Cancer research.

[13]  A. Oshima,et al.  Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy , 2010, The Pharmacogenomics Journal.

[14]  G. V. Ommen,et al.  Medical genomics , 2001, European Journal of Human Genetics.

[15]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[16]  N. Palanisamy,et al.  Genomic Loss of miR-486 Regulates Tumor Progression and the OLFM4 Antiapoptotic Factor in Gastric Cancer , 2011, Clinical Cancer Research.

[17]  R. Tibshirani,et al.  Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data , 2004, PLoS biology.

[18]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[19]  Gerard J. Nuovo,et al.  Erratum: Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1 (Journal of Biological Chemistry (2018) 293 (33394–33405) DOI: 10.1074/jbc.M804788200) , 2008 .

[20]  Y. Doki,et al.  The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. , 2010, Journal of hepatology.

[21]  J. Balko,et al.  A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer , 2009, BMC Cancer.

[22]  G. Marti,et al.  Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity , 2009, Molecular Cancer Therapeutics.

[23]  Kazuhiro Yoshida,et al.  Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. , 2010, The Lancet. Oncology.

[24]  Xi Chen,et al.  A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. , 2011, European journal of cancer.

[25]  S. Sofianos Japanese Classification of Gastric Carcinoma - 2nd English Edition - Response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria , 2001 .

[26]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[27]  Il-Jin Kim,et al.  DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer. , 2004, Biochemical and biophysical research communications.

[28]  Junxia Zhang,et al.  hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells , 2008, Brain Research.